{
  "docId": "019de076-b515-770b-a5e9-c449fc01e3f7",
  "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4",
  "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides",
  "authorId": "neurobo-pharmaceuticals",
  "authorName": "NeuroBo Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 25,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 39,
  "notes": "The slide shows two heatmaps (17 inflammation genes, 22 stellate cell activation genes) and a biological pathway diagram.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/10",
  "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7",
  "deckJsonHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7.json",
  "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "chart",
      "text": "Changes of 17 inflammation signaling-related genes",
      "attrs": null,
      "subkind": "heatmap",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4f67a75a-7a64-4e83-a1cc-8b8935b258ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.28,
        "y": 0.45
      },
      "kind": "chart",
      "text": "Changes of 22 stellate cell activation-related genes",
      "attrs": null,
      "subkind": "heatmap",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d7abdfa-7bd8-400f-9d2c-68036a9eeed2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.4,
        "x": 0.55,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Mechanism of GLP1 receptor activation",
      "attrs": null,
      "subkind": "value-chain",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "07cf7982-272e-47f3-b912-54f9f4f6fff2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "Effectively decreased hepatic inflammation; Reduced systemic inflammation and fibrosis biomarkers; Reduced hepatic lipid and collagen deposition in the liver of MASH mice",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2103703a-8800-413a-866c-61ae3d4b927f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.55,
        "y": 0.6
      },
      "kind": "list",
      "text": "Pancreas: Increase proliferation of beta cells, Prevent apoptosis, Increase insulin biosynthesis/secretion; Liver: Decrease glucose production; Stomach: Decrease gastric emptying; Brain: Decrease appetite",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "32b15a06-bd8f-4365-a99f-3096c1fdd950",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "GPR119 in Glucose Control when Co-Administered with Other Therapies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "68a101b8-99d2-45d2-8529-7c9291eb1d58",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "867b301f-e3fd-410d-8377-3297b84cb5fc",
      "evidence": "list/bullet components suggest a structured comparison, but no clear 2x2 matrix",
      "confidence": 0.7
    },
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "11f3fcfb-081c-4314-a1bb-8ef188583350",
      "evidence": "chart/heatmap components could suggest a waterfall effect but not clear",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 7,
      "beatId": "fc2a383c-968e-4c6a-836f-347c2e1bb09a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 7-14 detail the solution, including DA-1241 and its competitive differentiation",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 24,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e",
      "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)",
      "position": 1,
      "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}